Study details
Enrolling now
Alpha-Amino-3-Hydroxy-5-Methyl-4-Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response
Yale University
NCT IDNCT05915013ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
50
Study length
about 9.3 years
Ages
18–60
Locations
1 site in CT
About this study
Researchers are testing if a treatment combining ketamine and perampanel improves depression symptoms. The trial will examine how stimulating AMPAR receptors affects the anti-depressant response to ketamine in adults with treatment resistant depression.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Ketamine
- 2.Take Perampanel
- 3.Take Placebo
PhasePhase 1
DrugKetamine
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low10%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
ketamine (NMDA receptor antagonist; induces dissociative anesthesia and analgesia), perampanel
Drug routes
oral (Oral Tablet)
Body systems
Psychiatry / Mental Health